FTSE MIB
34.246,89 -116,86 (-0,34%) Dow Jones
38.367,92 -135,77 (-0,35%) Nasdaq
15.716,26 +19,62 (+0,12%) Nikkei 225
38.460,08 +907,92 (+2,42%) Petrolio
82,70 -0,66 (-0,79%) Bitcoin EUR
60.862,27 -1.659,35 (-2,65%)
Akero Therapeutics, Inc. (AKRO)
| Chiusura precedente | 21,00 |
| Aperto | 20,95 |
| Denaro | 20,60 x 200 |
| Lettera | 20,80 x 100 |
| Min-Max giorno | 20,65 - 21,26 |
| Intervallo di 52 settimane | 11,25 - 58,38 |
| Volume | |
| Media Volume | 1.396.324 |
| Capitalizzazione | 1,429B |
| Beta (5 anni mensile) | -0,38 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,89 |
| Prossima data utili | 13 mag 2024 - 17 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 48,38 |
GlobeNewswireAkero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
22% (28mg EFX) and 24% (50mg EFX) of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group experienced a three- or two-stage reversal of fibrosis with no worsening of NASH, compared to 0% for placebo 63% (28mg EFX) and 60% (50mg EFX) of patients experienced NASH resolution, representing statistically significant differences compared to 26% for placebo Investor webcast at 8:00
- GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical dataSOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday, October 10 at 8:00 a.m. ET to share topline week 36 results from its SYMMETRY study, a double-blind, placebo-controlled Phase 2b
- GlobeNewswire
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening of fibrosis Authors conclude robust data set indicates the potential of EFX to improve NASH histopathology and establish healthier whole-body metabolism SOUTH SAN FRANCISCO, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing trans
